Cibinetide, also known as ARA-290, is a synthetic 11-mer peptide that binds the tissue-protective receptor. ARA290 inhibits high glucose-induced apoptosis of NRK-52E cells. Cibinetide Protects Isolated Human Islets in a Stressful Environment and Improves Engraftment in the Perspective of Intra Portal Islet Transplantation. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception.
It is commonly used in kidney diseases: for the treatment of acute kidney injury, it can significantly reduce serum creatinine levels, improve renal function, and reduce the need for dialysis. Cardiovascular diseases: it has potential therapeutic effects on cardiovascular diseases such as myocardial infarction and heart failure, can improve cardiac function, and reduce cardiomyocyte apoptosis. Neurological diseases: it shows neuroprotective effects in the research of ischemic stroke, neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease, etc., and is expected to delay the progression of diseases.
Brand: Soarwin
CAS No.: 1208243-50-8
Molecular Formula: C51H84N16O21
EC Number: 200-001-8
Density: 1.56±0.1 g/cm3(Predicted)
